Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$10.50 USD
+0.50 (5.00%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $10.32 -0.18 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Tango Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 338 | 367 | 486 | 1 | -99,999 |
Receivables | 0 | 2 | 2 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 9 | 7 | 5 | 0 | NA |
Total Current Assets | 347 | 375 | 492 | 2 | NA |
Net Property & Equipment | 10 | 11 | 5 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 167 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 3 | 3 | 2 | 0 | NA |
Total Assets | 403 | 436 | 500 | 168 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 3 | 4 | 3 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 15 | 18 | 10 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 26 | 32 | 26 | 0 | NA |
Total Current Liabilities | 46 | 56 | 41 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 67 | 92 | 115 | 6 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 157 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 149 | 187 | 155 | 163 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 624 | 523 | 507 | 5 | NA |
Retained Earnings | -371 | -270 | -161 | 0 | NA |
Other Equity | 0 | -4 | -1 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 253 | 249 | 345 | 5 | NA |
Total Liabilities & Shareholder's Equity | 403 | 436 | 500 | 168 | NA |
Total Common Equity | 253 | 249 | 345 | 5 | 0 |
Shares Outstanding | 101.90 | 88.10 | 87.50 | 21.30 | NA |
Book Value Per Share | 2.48 | 2.83 | 3.94 | 0.23 | 0.00 |
Fiscal Year End for Tango Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 322 | 344 | 338 | 361 | 312 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 8 | 9 | 10 | 9 |
Total Current Assets | 328 | 352 | 347 | 371 | 321 |
Net Property & Equipment | 9 | 10 | 10 | 10 | 11 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 3 |
Total Assets | 381 | 406 | 403 | 428 | 379 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 4 | 3 | 3 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 14 | 15 | 11 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 24 | 23 | 26 | 27 | 34 |
Total Current Liabilities | 44 | 43 | 46 | 43 | 54 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 54 | 63 | 67 | 71 | 75 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 134 | 142 | 149 | 152 | 166 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 683 | 674 | 624 | 618 | 533 |
Retained Earnings | -435 | -409 | -371 | -340 | -318 |
Other Equity | 0 | 0 | 0 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 248 | 264 | 253 | 277 | 213 |
Total Liabilities & Shareholder's Equity | 381 | 406 | 403 | 428 | 379 |
Total Common Equity | 248 | 264 | 253 | 277 | 213 |
Shares Outstanding | 106.80 | 106.70 | 101.90 | 101.70 | 88.40 |
Book Value Per Share | 2.32 | 2.48 | 2.48 | 2.72 | 2.41 |